Chikungunya Vaccines

Authored by

Last reviewed

January 23, 2025

Fact checked by Holly Lutmer PharmD
Fact checked by Robert Carlson, MD

Content Overview

Chikungunya preventive vaccine has been approved and others are pending in 2025

Chikungunya Vaccines 2025

Like many vaccines, Chikungunya virus (CHIKV) vaccine technologies, such as live-attenuated virus vaccines, inactivated viral vaccines, recombinant viral vaccines, chimeric-alphavirus candidates, DNA vaccines, and virus-like particles, focus on optimizing the balance between efficacy, immunogenicity, and safety, says the World Health Organization (WHO).

Chikungunya Vaccine Approved

Valneva SE's IXCHIQ® (VLA1553) chikungunya vaccine was approved by the U.S. in 2023, in Canadia and Europe in 2024.

Chikungunya Vaccine Candidates 2025

The WHO says several advanced chikungunya vaccine candidates are approaching or undergoing regulatory review.

CHIKV-VLP is a CHIKV virus-like particle vaccine candidate produced by Bavarian Nordic A/S.

Bharat Biotech International Ltd's (BBIL) Chikungunya vaccine candidate (BBV87) is an inactivated whole virion vaccine candidate based on a strain derived from an East, Central, and South African genotype.

mRNA-1944 vaccine candidate encodes a fully human IgG antibody isolated initially from the B cells of a patient with a prior history of potent immunity against Chikungunya infection.

CD8+ T cell CHIKV Adaptive Vaccine candidate. Inclusion of the ligandome into the vaccine construct will require the selection of eight to twelve peptides from amongst the CHIKV peptide set (ligandome), all of which meet several specific criteria. In vitr, efficacy studies will then need to be completed.

The Access to Advanced Health Institute received an $18 million award from the National Institutes of Health to develop a temperature-stable, single-dose vaccine candidate for the chikungunya virus. The vaccine uses an innovative RNA platform technology.

A CHIKV vaccine candidate based on baculovirus displaying the chikungunya E1-E2 envelope confers protection against clinical challenges in mice. C57BL/6 mice were immunized with non-adjuvanted recombinant baculovirus-induced IgG antibodies against E2, with a predominant IgG2c subtype, neutralizing antibodies, and a specific IFN-γ CD8+ T-cell response. A second dose significantly boosted the antibody response.

U.S. CDC and Chikungunya Vaccines

At the U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) on October 23, 2024, reviewed Chikungunya vaccine presentations led by Edwin Asturias, M.D. On October 26, 2023, Dr. S Hills presented EtR and proposed policy options for chikungunya vaccine use among U.S. adults traveling abroad.

Chikungunya Vaccine Market

Market Research Future announced that the Chikungunya vaccine market is expected to grow at an annual rate of 10.12% from 2022 to 2032 and reach $500 million in sales annually.